Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?

Letter/Communication

Malik E Juweid, Brian Smith, Emmanuel Itti and Michel Meignan

Journal of clinical oncology, Vol.28(34), pp.e719-e720

12/01/2010

DOI: 10.1200/JCO.2010.30.4394

PMID: 20733137

View Online

Immunotherapy

Lymphoma, Large B-Cell, Diffuse - diagnostic imaging

Lymphoma, Large B-Cell, Diffuse - therapy

Biopsy

Humans

Positron-Emission Tomography - standards

Fluorodeoxyglucose F18

Antineoplastic Agents - therapeutic use

Positron-Emission Tomography - methods

Radiopharmaceuticals

Title: Subtitle: Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?
Creators: Malik E Juweid
Brian Smith
Emmanuel Itti
Michel Meignan
Resource Type: Letter/Communication
Publication Details: Journal of clinical oncology, Vol.28(34), pp.e719-e720
DOI: 10.1200/JCO.2010.30.4394
PMID: 20733137
NLM abbreviation: J Clin Oncol
ISSN: 0732-183X
eISSN: 1527-7755
Publisher: United States
Grant note: P30 CA086862 / NCI NIH HHS
Language: English
Date published: 12/01/2010
Academic Unit: Biostatistics; Holden Comprehensive Cancer Center
Record Identifier: 9983997364002771

29 Record Views